Animal data shows that testosterone administration increases the volume of some parenchymal organs. However, the effects of exogenous testosterone on solid abdominal organs in humans remain unknown. The present study evaluated the effects of testosterone administration on the volume of liver, spleen and kidneys in a dose-response trial. Young healthy men aged 18-50 years participating in the 5a-Reductase (5aR) Trial. All participants received monthly injections of 7.5 mg leuprolide acetate to suppress endogenous testosterone secretion and weekly injections of 50, 125, 300 or 600 mg of testosterone enanthate, and were randomized to receive either 2.5 mg dutasteride (5 a-reductase inhibitor) or placebo daily for 20 weeks. Liver, spleen and kidney volumes were measured at baseline and the end of treatment using 1.5-Tesla magnetic resonance imaging. The dose-effect of testosterone on changes in the volume of parenchymal organs was evaluated by linear regression model. The association between changes in total testosterone (TT) levels and changes in organ volumes were assessed. Testosterone administration increased liver volume dosedependently (17.4 cm 3 per 100 mg of weekly testosterone enanthate; p = 0.031); the increase in liver volume was positively associated with changes in TT levels (R 2 = 0.08, p = 0.024). A dose-dependent, but non-significant, increase in kidney volumes was also seen. Inclusion of dutasteride use into the models showed an independent association of randomization to dutasteride group with liver volume increase. In conclusion, Testosterone administration increased the liver volume in a dose-dependent manner. The potential changes in parenchymal organs should be considered when interpreting apparent changes in lean mass in response to anabolic interventions.
INTRODUCTION
Androgen deficiency is associated with loss of lean body mass and an increase in fat mass (Mauras et al., 1998) ; and androgen replacement reverses these adverse changes in body composition (Woodhouse et al., 2004; Bhasin et al., 2012) . Dual-energy X-ray absorptiometry (DXA) is the most widely used tool to monitor changes in body composition in response to anabolic interventions, including androgens (Guglielmi et al., 2016) . The DXA scan measures the transmission of high and low energy X-ray beams through the body. The energy of the beams is differently attenuated as it passes through various tissues depending on their composition, quantifying three distinct components: bone mineral content, fat tissue and lean soft tissue (Toombs et al., 2012) . The lean body mass measured by DXA scan takes into account the total body water (St-Onge et al., 2004) and the mass of the solid parenchymal organs (Toombs et al., 2012) . Therefore, changes in lean body mass in response to anabolic interventions do not reflect change in muscle mass alone.
Testosterone administration is associated with salt and water retention. Indeed, testosterone administration in men with central hypogonadism due to panhypopituitarism results in a substantial increase in extracellular water (Johannsson et al., 2005) . These changes in water metabolism induced by testosterone confound the measurement of lean mass on DXA. Interestingly, animal data shows that exogenous testosterone administration also stimulates increase in the size of visceral organs. In the adult rat, high-dose testosterone administration for 12-16 weeks has been shown to increase weight of the kidneys, even after correction for body weight . Testosterone administration to castrated juvenile rats also resulted in larger kidneys when compared to sham controls (Shortliffe et al., 2014) . Similarly, androgens have also been shown to have stimulatory effects on the liver and the spleen. Castration of male rats results in a decrease in splenic mass which is partially reversed by testosterone administration . Similarly, administration of androgens increases the liver size in other animal studies (Hickson et al., 1976; Ferrandez et al., 1996; Friedel et al., 2006; Vieira et al., 2008) . Data from population studies complement these animal data. Among healthy adults, men have larger splenic, hepatic and total renal volume compared to age-matched women (Chouker et al., 2004; Chow et al., 2016; Roseman et al., 2016) . This effect of sex on hepatic and splenic volume persists even after adjustment for body size (Chouker et al., 2004; Chow et al., 2016) .
Although the data discussed above from animal and population studies are convincing, the effects of testosterone administration on parenchymal organs have not been studied in the setting of a clinical trial. Therefore, the 5a-Reductase (5aR) Trial provided the opportunity to evaluate the effects of testosterone administration on renal, splenic and hepatic volume in a dose-dependent fashion in healthy young men (Bhasin et al., 2012) .
MATERIAL AND METHODS

Study design and participants
The 5a-Reductase (5aR) Trial was a randomized, double-blind, placebo-controlled parallel-group trial (Bhasin et al., 2012) . The trial was designed to evaluate the importance of the conversion of testosterone to 5a-dihydrotestosterone (DHT) on the effects of testosterone on muscle mass, strength, sexual function, prostate volume, sebum production, hematocrit and blood lipids in healthy eugonadal men. The first participant was enrolled in May 2005 and the last participant completed the trial in June 2010. The study was approved by the institutional review board of Boston University and Brigham and Women's Hospital, and all participants gave written informed consent. The trial is registered at ClinicalTrials.gov (identifier: NCT00493987).
The details for eligibility and exclusion criteria for the 5aR trial have been previously published (Bhasin et al., 2012) . Briefly, healthy men aged 18-50 years with normal testosterone levels (300-1200 ng/dL) were allowed to enroll in the study. Men who had a history of prostate cancer, lower urinary tract symptom score >20, body weight >135 kg, uncontrolled hypertension, hematocrit level >51%, prostate-specific antigen (PSA) level >4 ng/mL, aspartate aminotransferase or alanine aminotransferase >1.5 times the upper limit of normal, creatinine level >2 mg/dL, or were receiving glucocorticoids, growth hormone, androgens, or 5a-reductase inhibitors were excluded from the study.
Procedures
Endogenous testosterone secretion was suppressed by monthly intramuscular injections of 7.5 mg of leuprolide acetate (Lupron depot; TAP Pharmaceuticals, Lake Forest, IL, USA) starting on the day of randomization. The subjects then received weekly administration of four graded doses of testosterone enanthate (TE) selected to generate plasma testosterone levels ranging from subphysiological to supraphysiological. These doses were based on dose-response studies in healthy men (Bhasin et al., 2001 (Bhasin et al., , 2005 . A randomization table was used to allocate individuals to one of eight study groups (placebo plus 50, 125, 300, or 600 mg/week of intramuscular TE for 20 weeks or 2.5 mg/day of dutasteride plus 50, 125, 300, or 600 mg/week of intramuscular TE for 20 weeks).
Imaging
Body composition was measured using DXA (Hologic QDR 4500A), after calibration using a soft-tissue phantom (Kim et al., 2002) before and at the 19th week of treatment.
Participants underwent 1.5-T magnetic resonance imaging (MRI; Philips Medical Systems, Andover, MA, USA) of the abdomen and pelvis, using an axial mixed-fast-spin echopulse sequence (slice thickness: 5-8 mm; interslice distance: 2 mm) before and at the 18th week of treatment. Kidneys, liver and spleen volumes were segmented using an AW 4.4 Workstation with Volume Viewer 3.1 (General Electric, Chicago, IL, USA) by three radiologists (ERT, KM, SLC) who were blinded to treatment allocation of participants and who were trained by one single expert radiologist (SA) on methodology for volume segmentation that was based on published literature (Heymsfield et al., 1979) . Each MRI was read by all three radiologists independently and then measurements were averaged. During volume segmentation, each organ was manually contoured along its margins on each axial MR image; at areas with crossing hilar vasculature, the contour was continued along the trajectory of the parenchymal margin through and past the vessel. At the completion of volume segmentation for each organ, the volume provided by the segmentation tool (calculated based on the product of contoured area per axial slice with axial slice thickness) was recorded. Only men who had pre-and post-randomization MRI were included in the secondary analyses discussed in the present work.
Hormone assays
Blood samples for quantification of testosterone were collected before and at the end of the trial. Total testosterone and dihydrotestosterone (DHT) were measured using liquid chromatography tandem mass spectrometry (LC-MS/MS) with sensitivity of 2 ng/dL . The interassay coefficient of variation for the testosterone assay was 7.7% at 241 ng/dL, 4.4% at 532 ng/dL, and 3.3% at 1016 ng/dL of testosterone. Free testosterone was calculated (Mazer, 2009 ). Sex-hormone binding globulin (SHBG) was measured using an immunofluormetric assay with sensitivity of 2.5 nmol/L (Basaria et al., 2010).
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Safety monitoring
During the study, blood counts and chemistry, including liver function tests and renal function, were assessed at baseline and during weeks 4, 8, 12 and 16. An independent Data and Safety Monitoring Board reviewed study's progress and safety data every 6 months.
Statistical analysis
Primary analyses were performed on subjects who had baseline and end of study measurements available for organs volume. Baseline characteristics for each dose were presented as means and standard deviations and changes from baseline, for body composition and laboratory data, were expressed as means and 95% confidence intervals (CI). Feasibility of the statistical assumptions was explored graphically and quantitatively. Change in outcomes was assessed using multiple linear regression models with dose-effect ordinal variable adjusted for volume, age, height and weight measured at the beginning of the study. Estimates of adjusted volume changes with corresponding 95% CIs were provided per 100 mg per week dose change of testosterone enanthate. Assessment of relative strength of dose effect on change from baseline in organ volume measurements was supported by computation of R-squared and partial R-squared metrics. To explore association between total and free testosterone levels with volume change simple linear regression analysis was employed. R-squared and corresponding p-values were provided to support graphical assessment of this relationship.
Sensitivity analyses, investigating potential modification of dose effect, were examined by inclusion of dutasteride treatment factor in all primary outcome models, and estimates of testosterone dose were compared between model with and without dutasteride assignment.
Analyses were performed using SAS v.9.3 (SAS Institute, Cary, NC, USA) and, R software version 2.15.1. and GRAPHPAD PRISM version 6 (GraphPad Software, Inc., La Jolla, CA, USA). Statistical tests were two-sided with Type I error assumption of 0.05.
RESULTS
Participants
Of the 139 subjects randomized to one of the treatment groups, 102 completed the 20 weeks of intervention. Of those, 62 had available MRI data on organ volumes at both time points and formed the analytical sample. The mean age was 37 years (range 24-50 years) and mean body mass index (BMI) was 26.5 kg/m 2 (20.0-36.9 kg/m 2 ).
For the purpose of the analyses, participants receiving placebo or dutasteride were pooled according to the dosage of TE they were allocated to, generating 4 treatment groups (50, 125, 300 or 600 mg of TE per week). The potential effect of dutasteride treatment was assessed in the linear regression models. Baseline characteristics were similar among the 4 groups (Table 1) .
Hormones and body composition
Plasma levels of total and free testosterone increased in a dose-dependent manner in all groups, while levels of SHBG decreased (Fig. 1A-C) . Total DHT decreased similarly in subjects receiving dutasteride and increased in a dose-dependent manner in those receiving placebo (Fig. 1D) .
Body weight and lean body mass increased in a dose dependent manner, while fat mass decreased (Fig. 2) .
Organ volumes
Liver volume
Mean changes in liver volume from baseline in each testosterone dose group are shown in Fig. 3A . Changes ranged from À303 to 471 cm 3 . The linear regression model which adjusted for age, body weight, height and baseline liver volume showed that there was a significant dose-effect of testosterone (estimated change = 17.4 cm 3 /100 mg of TE (95% CI: 1.63 to 33.13 cm 3 /100 mg of TE); p = 0.031; Fig. 6 ). Absolute changes in liver volume were positively associated with changes in serum total testosterone levels (R 2 = 0.083; p = 0.024; Fig. 3B ), further confirming testosterone effect. No clinically significant changes in liver function tests were observed in any of the groups.
Effect of 5a-reductase inhibition on liver volume Inclusion of dutasteride use into the models showed an independent association of randomization to dutasteride group with liver volume increase; however, it did not change the magnitude of the testosterone effect [estimated change = 16.10 cm 3 / 100 mg of TE (95% CI: 0.9-31.3 cm 3 /100 mg of TE); p = 0.038 for model with dutasteride].
Spleen volume
Mean changes from baseline for spleen volume are shown in Fig. 4A . The linear regression adjusted for age, body weight, height and baseline spleen volume did not show a significant dose-effect for testosterone on spleen volume (estimated change = 2.65 cm 3 /100 mg of TE (95% CI: À3.14 to 8.45 cm 3 / 100 mg of TE); p = 0.363; Fig. 6 ). Changes in spleen volume were not associated with changes in total testosterone levels (R 2 = 0.005; p = 0.575; Fig. 4B ).
Effect of 5a-reductase inhibition on splenic volume Inclusion of dutasteride use into the models did not show an association of randomization to dutasteride group with splenic volume increase [estimated change = 2.12 cm 3 /100 mg of TE (95% CI: À3.54 to 7.77 cm 3 /100 mg of TE); p = 0.456 for model
with dutasteride].
Total kidney volume
Mean changes from baseline for total kidney volume are shown in Fig. 5A . Changes ranged from À88 to 135 cm 3 . The linear regression model adjusted for age, body weight, height and baseline total kidney volume showed a trend towards the dose-effect for testosterone (estimated change = 4.04 cm 3 /100 mg of TE (95% CI: À0.54 to 8.62 cm 3 /100 mg of TE); p = 0.083; Fig. 6 ). Changes in total kidney volume were not associated to changes in total testosterone levels (R 2 = 0.002; p = 0.760; Fig. 5B ). No clinically significant changes in renal function tests were observed.
Effect of 5a-reductase inhibition on total kidney volume Inclusion of dutasteride use into the models did not show an association of randomization to dutasteride group with total kidney volume increase [estimated change = 4.00 cm 3 /100 mg of TE (95% CI: À0.64 to 8.64 cm 3 /100 mg of TE); p = 0.090 for model with dutasteride].
Sum of all organs
When considering changes in volumes of liver, spleen and kidneys together, expressed as a sum of three organ measurements, variations in volume ranged from À429 to 570 cm 3 , and showed a positive trend with dose increase. Considering the density of these organs (Snyder et al., 1975) , the average percent contribution of the weight change of the three organs to the total lean body mass change was on average 4-5%.
DISCUSSION
The present study shows that exogenous testosterone administration induced a dose-dependent increase in hepatic volume and a trend towards an increase in renal volume. These results are consistent with previous animal studies showing trophic effect of androgens on parenchymal organs Hickson et al., 1976; Ferrandez et al., 1996; Friedel et al., 2006; Vieira et al., 2008; Shortliffe et al., 2014; Chen et al., 2016) . These findings are also consistent with epidemiologic studies showing men having larger parenchymal organs after adjustment for age and body size compared to women (Chouker et al., 2004; Chow et al., 2016; Roseman et al., 2016) . Since DXA takes into account the mass of the parenchymal organs when assessing lean body mass, the aforementioned effects should be taken into account when evaluating changes in lean body mass observed by DXA in response to androgen therapy.
Previous animal studies have shown that administration of androgens to rats increases liver mass (Hickson et al., 1976; Friedel et al., 2006; Vieira et al., 2008) . In humans, liver volume is higher in young men than in young women, even after adjustment for body size and age, an effect believed to be mediated by higher endogenous serum testosterone levels in men (Chouker et al., 2004) . Indeed, this gender influence on liver volume is lost as men get older, suggesting that the age-related decline in serum testosterone level might explain this phenomenon (Chouker et al., 2004) . Similar to the trophic effects on the liver, administration of testosterone and other androgens, such as nandrolone and stanozolol, to rodents also increases weight of the spleen (Ferrandez et al., 1996) . The trophic effects of androgens on the spleen is further corroborated by data showing that castration of male rats results in a decrease in splenic size, which is partially reversed by administration of testosterone . In healthy humans, the spleen volume in men is higher than in age-matched women even after correction for body weight (Chow et al., 2016) . In addition to liver and spleen, androgens also stimulate renal size in animals. In the adult rat, high dose testosterone propionate (7.5 mg/week for 12 to 16 weeks) increases renal weight . Similarly, weekly administration of TE for 16 weeks resulted in higher total renal weight in castrated juvenile rats compared to controls (Shortliffe et al., 2014) . In humans, total kidney volume is higher in men than in women (Roseman et al., 2016) . The work presented here not only supports these data from animal and population studies but also shows that this trophic effect of androgens on liver volume is dose-dependent.
The specific contribution of DHT on the trophic effects of testosterone on parenchymal organs remains unclear. In a small 3-week trial in healthy young men, dutasteride treatment promoted hepatic lipid accumulation and induced hepatic insulin resistance, possibly due to impaired cortisol clearance by 5a-reductase activity (Hazlehurst et al., 2016) . This might explain the independent association of dutasteride use and increase in liver volume observed in the present work.
The increase in liver size observed with testosterone treatment was not accompanied by elevated liver function tests, suggesting that there was no liver injury or inflammatory response that could account for the change in hepatic volume. It is possible that testosterone might have direct effect on hepatocyte Data are expressed as mean AE SD (n). When n is not displayed for organ volume, the totality of the sample for the group is assumed. BMI, body mass index; DHT, dihydrotestosterone; SHBG, sex hormone-binding globulin.
proliferation and activity. Activation of the androgen receptor has been shown to downregulate E-cadherin gene expression (Liu et al., 2008) , which mediates contact inhibition of proliferation through interaction with the Hippo signaling-pathway, a major regulator of organ size (Kim et al., 2011) . Additionally, the androgen receptor signaling-pathway is known to cross- Figure 1 Data are displayed as mean and error bars are 95% confidence interval for change from baseline in (A) total testosterone, (B) free testosterone, (C) SHBG and (D) DHT for each weekly testosterone enanthate dosage group. On (D), black bars represent subjects allocated to placebo subgroup, while gray bars are subjects that received dutasteride. p-values were calculated by linear regression model adjusted for baseline value. TE, testosterone enanthate; SHBG, sex hormone-binding globulin; DHT, dihydrotestosterone.
talk with the aryl hydrocarbon receptor (AhR) pathway (Ohtake et al., 2008) ; AhR regulates normal development of the liver (Schmidt et al., 1996) and stimulation of AhR increases liver mass in mammals (McConnell et al., 1978; Moore et al., 1979) by stimulating proliferation of both smooth and rough endoplasmic reticulum (Fowler et al., 1973) . Although evidence from rodent models suggested that testosterone would have a dose-effect on spleen size, the present work did not find a significant effect of testosterone on spleen volume. The differences in the location and physiologic regulation of erythropoiesis might account for this inter-species difference. In mice -in contrast to humans -the spleen is the site of stress erythropoiesis, which may be stimulated by testosterone (Paulson et al., 2011; Kim et al., 2015) . It is also well established that testosterone has hypertrophic effects on the renal mass in rodents, possibly due to stimulation of polyamine pathway ( Levillain et al., 2005; MacLean et al., 2010; Shortliffe et al., 2014) . Although we observed a trend towards a testosterone dose effect, these changes were not statistically significant. It is possible that individual variations in sympathetic tone might have attenuated the effect of testosterone on kidney volume. Testosterone has been shown to counteract sympathetic tone of the afferent renal arteriole (Lu et al., 2012) , which in turn increases renal blood flow and consequently, influences renal volume (Eikefjord et al., 2016) . It is also possible that the study did not have sufficient statistical power due to the small sample size. The results of the present work are particularly relevant for the assessment of efficacy of anabolic therapeutic strategies for sarcopenic and mobility limited patients. Most studies in these populations show that androgen therapy increases whole body lean mass, with an average increase of 1-2 kg (Kenny et al., 2010; Srinivas-Shankar et al., 2010; Travison et al., 2011; Papanicolaou et al., 2013) , depending upon the testosterone dose. As testosterone can increase liver mass (Johannsson et al., 2005) , the apparent increases in total lean mass quantified by DXA may not be due to gains in skeletal muscle mass alone. If the aim is to assess the efficacy of androgens in increasing skeletal muscle mass, alternate methods, such as the measurement of appendicular lean mass rather than total lean mass (which eliminates the confounding from visceral organs but still does not eliminate confounding of water retention) or the use of D 3 -creatine excretion (Clark et al., 2014) , which has shown good correlation with changes in muscle volume measured by magnetic resonance imaging, might be more appropriate.
The present study has several strengths and some limitations. The strengths include the randomized double-blind study design, the inclusion of young healthy men, which obviated confounding due to age or co-morbid conditions. We used a range of testosterone doses that resulted in a range of circulating testosterone concentrations, extending from sub-physiological to supra-physiological levels. These hypotheses were not pre-specified and therefore should be viewed as exploratory. The sample size was relatively small and might have resulted in an insufficient power to detect the effect of testosterone on the kidneys and the spleen.
In summary, exogenous testosterone therapy increases liver volume in a dose-dependent manner. These findings have implications when interpreting changes in lean body mass in response to anabolic interventions using various androgens. Evaluation of efficacy of androgens should focus on more reliable techniques of measurement of muscle mass to avoid any potential confounding by visceral organs.
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